Chapter 6: Tuberculosis preventive treatment in adults

References

• Getahun H, Matteelli A, Chaisson R, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–2135. doi:10.1056/NEJMra1405427.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Operational handbook on tuberculosis: tuberculosis preventive treatment. 2020. https://www.who.int/publications/i/item/9789240002906. Accessed March 1, 2022.
   Google Scholar
• Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. Adv Tuberc Res. 1969;17:28–106.
   Google Scholar
• Long R, Ellis E. Canadian Tuberculosis Standards. 6th ed. Canadian Lung Association, Public Health Agency of Canada, Tuberculosis Prevention and Control; 2007.
   Google Scholar
• Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res. 1976;19:1–63.
   PubMedGoogle Scholar
• Sutherland I. The evolution of clinical tuberculosis in adolescents. Tubercle. 1966;47:308.
   Google Scholar
• Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–2166. doi:10.1056/NEJMoa1104875.
   PubMed Web of Science ®Google Scholar
• Villarino M, Scott N, Weis S, Tuberculosis Trials Consortium, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169(3):247–255. JAMA Pediatr. 2015 Sep;169(9):878. doi:10.1001/jamapediatrics.2014.3158.
   PubMed Web of Science ®Google Scholar
• Pease C, Hutton B, Yazdi F, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17(1):1–11. doi:10.1186/s12879-017-2377-x.
   PubMedGoogle Scholar
• Zenner D, Schlossberg D. Crisis-Affected Populations and Tuberculosis. Microbiol Spectr. 2017;5(1). doi:10.1128/microbiolspec.TNMI7-0031-2016.
   Google Scholar
• Sandul AL, Nwana N, Holcombe JM, et al. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection. Clin Infect Dis. 2017;65(7):1085–1093. doi:10.1093/cid/cix505.
   PubMed Web of Science ®Google Scholar
• Bliven-Sizemore E, Sterling T, Shang N, The TB Trials Consortium, et al. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int j Tuberc Lung Dis. 2015;19(9):1039–1044. doi:10.5588/ijtld.14.0829.
   PubMed Web of Science ®Google Scholar
• Sterling TR, Moro RN, Borisov AS, et al. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clin Infect Dis. 2015;61(4):527–535. doi:10.1093/cid/civ323.
   PubMed Web of Science ®Google Scholar
• Pease C, Hutton B, Yazdi F, et al. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf. 2018;27(6):557–566. doi:10.1002/pds.4423.
   PubMed Web of Science ®Google Scholar
• Belknap RW, Holland D, Feng P, TB Trials Consortium iAdhere Study Team, et al. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med. 2017;167(10):689–697. doi:10.7326/M17-1150.
   PubMed Web of Science ®Google Scholar
• Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC. Am J Transplant. 2020;20(4):1196–1206. doi:10.1111/ajt.15841.
   Web of Science ®Google Scholar
• Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009;179(11):1055–1060. doi:10.1164/rccm.200901-0153OC.
   PubMed Web of Science ®Google Scholar
• Doan TN, Fox GJ, Meehan MT, et al. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study. J Antimicrob Chemother. 2019;74(1):218–227. doi:10.1093/jac/dky403.
   PubMed Web of Science ®Google Scholar
• Shepardson D, Marks SM, Sterling TR, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013;17(12):1531–1537. doi:10.5588/ijtld.13.0423.
   PubMed Web of Science ®Google Scholar
• Pease C, Alvarez GG, Mallick R, et al. Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting. BMJ Open. 2021;11(5):e047514 doi:10.1136/bmjopen-2020-047514.
   PubMed Web of Science ®Google Scholar
• Menzies D, Adjobimey M, Ruslami R, et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med. 2018;379(5):440–453. doi:10.1056/NEJMoa1714283.
   PubMed Web of Science ®Google Scholar
• Diallo T, Adjobimey M, Ruslami R, et al. Safety and Side Effects of Rifampin versus Isoniazid in Children. N Engl J Med. 2018;379(5):454–463. Aug 2 doi:10.1056/NEJMoa1714284.
   PubMed Web of Science ®Google Scholar
• Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ. 2020;368:m549. doi:10.1136/bmj.m549.
   PubMedGoogle Scholar
• Bastos ML, Campbell JR, Oxlade O, et al. Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings. Ann Intern Med. 2020;173(3):169–178. doi:10.7326/M19-3741.
   PubMed Web of Science ®Google Scholar
• Campbell JR, Al-Jahdali H, Bah B, et al. Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. Clin Infect Dis. 2021;73(9):e3545–e3554. doi:10.1093/cid/ciaa1169.
   Google Scholar
• Zunza M, Gray DM, Young T, Cotton M, Zar HJ. Isoniazid for preventing tuberculosis in HIV-infected children. Cochrane Database Syst Rev. 2017;8(8):CD006418. doi:10.1002/14651858.CD006418.pub3
   PubMedGoogle Scholar
• Akolo C, Adetifa I, Shepperd S, Volmink J, Akolo C. Treatment of Latent Tuberculosis Infection in HIV Infected Persons. Cochrane Library. 2010;2010(1):CD000171–CD000171. doi:10.1002/14651858.CD000171.pub3.
   PubMedGoogle Scholar
• Smieja M, Marchetti C, Cook D, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000;2019(5):CD001363–CD001363.
   Google Scholar
• Comstock G. How much isoniazid is needed for prevention of tuberculosis in immunocompetent adults? Int J Tuberc Lung Dis. 1999;3(10):847–850.
   PubMed Web of Science ®Google Scholar
• Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis. 1972;106(3):357–365. doi:10.1164/arrd.1972.106.3.357.
   PubMedGoogle Scholar
• Ronald LA, FitzGerald JM, Bartlett-Esquilant G, et al. Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs. Eur Resp J. 2020;55(3):1902048. doi:10.1183/13993003.02048-2019.
   Google Scholar
• Kopanoff DE, Snider DE, Jr, Caras GJ. Isoniazid-related hepatitis. Am Rev Respir Dis. 1978;117(6):991–1001.
   PubMed Web of Science ®Google Scholar
• Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281(11):1014–1018. doi:10.1001/jama.281.11.1014.
   PubMed Web of Science ®Google Scholar
• LoBue PA, Moser KS. Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002. Int J Tuberc Lung Dis. 2005;9(5):501–506.
   PubMed Web of Science ®Google Scholar
• Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest. 2005;128(1):116–123. doi:10.1378/chest.128.1.116.
   PubMed Web of Science ®Google Scholar
• Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ. Isoniazid-related fatal hepatitis. West J Med. 1996;164(6):486–491.
   PubMedGoogle Scholar
• Snider DE, Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis. 1992;145(2 Pt 1):494–497. doi:10.1164/ajrccm/145.2_Pt_1.494.
   PubMedGoogle Scholar
• Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med. 1997;337(12):801–808. doi:10.1056/NEJM199709183371201.
   PubMed Web of Science ®Google Scholar
• International Union Against Tuberculosis Committee on Prophylaxis IUAT. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bulletin of the World Health Organization. 1983;60(4):555–564.
   Web of Science ®Google Scholar
• Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet. 1998;351(9105):786–792. doi:10.1016/S0140-6736(97)06532-X.
   PubMed Web of Science ®Google Scholar
• Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS. 1998;12(18):2447–2457. doi:10.1097/00002030-199818000-00014.
   Web of Science ®Google Scholar
• Zar HJ, Cotton MF, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007;334(7585):136. doi:10.1136/bmj.39000.486400.55.
   PubMedGoogle Scholar
• Alvarez GG, Van Dyk D, Mallick R, et al. The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study. Int J Circumpolar Health. 2020;79(1):1758501. doi:10.1080/22423982.2020.1758501.
   Web of Science ®Google Scholar
• Pease C, Zwerling A, Mallick R, et al. The Latent Tuberculosis Infection Cascade of Care in Iqaluit, Nunavut, 2012-2016. BMC Infect Dis. 2019;19(1):890–890. doi:10.1186/s12879-019-4557-3.
   PubMed Web of Science ®Google Scholar
• Geijo MP, Herranz CR, Vaño D, García AJ, García M, Dimas JF. [Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial]. Enferm Infecc Microbiol Clin. 2007;25(5):300–304. doi:10.1157/13102264.
   PubMed Web of Science ®Google Scholar
• Martínez Alfaro E, Solera J, Serna E, et al. Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis. Med Clin (Barc). 1998;111((11):401–404.
   PubMed Web of Science ®Google Scholar
• Jiménez-Fuentes MA, de Souza-Galvao ML, Mila Augé C, Solsona Peiró J, Altet-Gómez MN. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. Int J Tuberc Lung Dis. 2013;17(3):326–332. doi:10.5588/ijtld.12.0510.
   PubMed Web of Science ®Google Scholar
• Hong Kong Chest Service Tuberculosis Research Centre. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis. 1992;145(1):36–41.
   PubMedGoogle Scholar
• Martinson NA, Barnes GL, Moulton LH, et al. New Regimens to Prevent Tuberculosis in Adults with HIV Infection. N Engl J Med. 2011;365(1):11–20. doi:10.1056/NEJMoa1005136.
   PubMed Web of Science ®Google Scholar
• Swindells S, Ramchandani R, Gupta A, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019;380(11):1001–1011. doi:10.1056/NEJMoa1806808.
   PubMed Web of Science ®Google Scholar
• Johns Hopkins University. Treatment Success and Safety of 4 Weeks of Daily Rifapentine and Isoniazid (1HP) vs. 12 Weeks of Weekly Rifapentine and Isoniazid (3HP) for Prevention of Tuberculosis in HIV-uninfected Individuals (1v3HP for TPT in HIV-uninfected Individuals). Clinical trial registration. 2021. https://clinicaltrials.gov/ct2/show/NCT04703075. Accessed December 24, 2019.
   Google Scholar
• Marks SM, Mase SR, Morris SB. Systematic Review, Meta-Analysis, and Cost-Effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2017;64(12):1670–1677. doi:10.1093/cid/cix208.
   PubMed Web of Science ®Google Scholar
• Bamrah S, Brostrom R, Dorina F, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis. 2014;18(8):912–918. doi:10.5588/ijtld.13.0028.
   PubMed Web of Science ®Google Scholar
• Fox G, Nguyen C, Nguyen T, et al. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial. BMJ Open. 2020;10(1):e033945. doi:10.1136/bmjopen-2019-033945.
   PubMed Web of Science ®Google Scholar
• Seddon J, Garcia-Prats A, Purchase S, et al. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). Trials. 2018;19(1):693. doi:10.1186/s13063-018-3070-0.
   PubMedGoogle Scholar
• National Institute of Allergy and Infectious Diseases (NIAID). Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB). Clinical trial registration. 2021. https://clinicaltrials.gov/ct2/show/NCT03568383. Accessed December 22, 2021.
   Google Scholar
• Yanes-Lane M, Ortiz-Brizuela E, Campbell J, et al. Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. PLoS Med. 2021;18(9):e1003738. doi:10.1371/journal.pmed.1003738.
   PubMed Web of Science ®Google Scholar
• Podany A, Leon-Cruz J, Hakim J, AIDS Clinical Trials Group A5279 Team, et al. Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. J Antimicrob Chemother. 2021;76(3):718–721. doi:10.1093/jac/dkaa470.
   PubMed Web of Science ®Google Scholar
• Bhatt NB, Barau C, Amin A, ANRS 12146-CARINEMO Study Group, et al. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. Antimicrob Agents Chemother. 2014;58(6):3182–3190. doi:10.1128/AAC.02379-13.
   PubMed Web of Science ®Google Scholar
• Podany AT, Bao Y, Swindells S, et al. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis. 2015;61(8):1322–1327. doi:10.1093/cid/civ464.
   PubMed Web of Science ®Google Scholar
• Dooley KE, Savic R, Gupte A, et al. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. Lancet HIV. 2020;7(6):e401–e409. doi:10.1016/S2352-3018(20)30032-1.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD). https://www.who.int/hiv/pub/arv/DTG-TLD-arv_briefing_2018.pdf. Accessed March 1, 2022.
   Google Scholar
• Weiner M, Egelund EF, Engle M, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69(4):1079–1085. doi:10.1093/jac/dkt483.
   PubMed Web of Science ®Google Scholar
• Franks AL, Binkin NJ, Snider DE, JrRokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep. 1989;104(2):151–155.
   PubMed Web of Science ®Google Scholar
• Gupta A, Montepiedra G, Aaron L, IMPAACT P1078 TB APPRISE Study Team, et al. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. N Engl J Med. 2019;381(14):1333–1346. doi:10.1056/NEJMoa1813060.
   PubMed Web of Science ®Google Scholar
• Moro RN, Scott NA, Vernon A, et al. Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials. Ann Am Thorac Soc. 2018;15(5):570–580. doi:10.1513/AnnalsATS.201704-326OC.
   PubMed Web of Science ®Google Scholar
• Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med. 2012;185(7):779–784. doi:10.1164/rccm.201106-1083OC.
   PubMed Web of Science ®Google Scholar
• Malhamé I, Cormier M, Sugarman J, Schwartzman K. Latent Tuberculosis in Pregnancy: A Systematic Review. PLoS One. 2016;11(5):e0154825. doi:10.1371/journal.pone.0154825.
   PubMed Web of Science ®Google Scholar
• Snider DE, Jr, Powell K. Should women take antituberculosis drugs and breast-feed? Arch Intern Med. 1984;144(3):589–590. doi:10.1001/archinte.1984.00350150199040.
   PubMedGoogle Scholar
• American Academy of Pediatrics. Red Book 2021: Report of the Committee of Infectious Diseases 2021. 2021.
   Google Scholar
• Campbell J, Trajman A, Cook V, et al. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis. 2020;20(3):318–329. doi:10.1016/S1473-3099(19)30575-4.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang H, Xin H, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J. 2018;52(6):1801470. doi:10.1183/13993003.01470-2018.
   PubMed Web of Science ®Google Scholar
• Huang HL, Huang WC, Lin Kd, et al. Completion Rate and Safety of Programmatic Screening and Treatment for Latent Tuberculosis Infection in Elderly Patients with Poorly Controlled Diabetic Mellitus: A Prospective Multicenter Study. Clin Infect Dis. 2021; doi:10.1093/cid/ciab209.
   Google Scholar
• Haas MK, Aiona K, Erlandson KM, Belknap RW. Higher Completion Rates with Self-administered Once-weekly Isoniazid-Rifapentine versus Daily Rifampin in Adults with Latent Tuberculosis. Clin Infect Dis. 2020; doi:10.1093/cid/ciaa1364.
   Web of Science ®Google Scholar
• Romanowski K, Rose C, Cook V, et al. Effectiveness of Latent TB Screening and Treatment in People Initiating Dialysis in British Columbia, Canada. Can J Kidney Health Dis. 2020;7(2020):205435812093710–205435812093104. doi:10.1177/2054358120937104.
   Google Scholar
• Lin S-Y, Chiu Y-W, Lu P-L, et al. Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection in Hemodialysis Patients: High Rates of adverse events. J Microbiol Immunol Infect. 2019;52(1):158–162. doi:10.1016/j.jmii.2018.05.003.
   Google Scholar
• Chiang LY, Baumann B, Romanowski K, et al. Latent Tuberculosis Therapy Outcomes in Dialysis Patients: A Retrospective Cohort. Am J Kidney Dis. 2021;77(5):696–703. doi:10.1053/j.ajkd.2020.06.017.
   Web of Science ®Google Scholar
• Menzies D. Issues in the management of contacts of patients with active pulmonary tuberculosis. Can J Public Health. 1997;88(3):197–201.
   Web of Science ®Google Scholar
• Andrews J, Noubary F, Walensky R, Cerda R, Losina E, Horsburgh C. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis. 2012;54(6):784–791. doi:10.1093/cid/cir951.
   PubMed Web of Science ®Google Scholar
• Lam CK, McGinnis Pilote K, Haque A, Burzynski J, Chuck C, Macaraig M. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study. J Med Internet Res. 2018;20(11):e287. doi:10.2196/jmir.9825.
   PubMed Web of Science ®Google Scholar
• Holzschuh EL, Province S, Johnson K, et al. Use of Video Directly Observed Therapy for Treatment of Latent Tuberculosis Infection - Johnson County, Kansas, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(14):387–389. doi:10.15585/mmwr.mm6614a3.
   Web of Science ®Google Scholar
• BC Centre For Disease Control. About Tuberculosis. Accessed December 25, 2021. http://www.bccdc.ca/health-info/diseases-conditions/tuberculosis.
   Google Scholar
• Menzies D, Dion M, Francis D, et al. In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection. Int J Tuberc Lung Dis. 2005;9(12):1343–1348.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Operational Handbook on Tuberculosis. 2021. 90. chap 7. Adherence to TB preventive treatment.
   Google Scholar
• McGill University Health Centre. Research Institute of the McGill University Health Centre. 2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB: a 3-arm Randomized Trial. Clinical trial registration. 2021. https://clinicaltrials.gov/ct2/show/NCT03988933. November 1, 2021. Accessed December 22. 2021.
   Google Scholar